Estrategias de tratamiento en tumores Neuroendocrinos: desde análogos de Somatostatina hasta la terapia con Radionúclidos

TARGETED AGENTS

CABOZANTINIB

RECIST RESPONSE PROFILE BY PRIOR THERAPY:

PANCREATIC NETS

Chan J, et al. J Clin Oncol 2017; 35, no. 4_suppl 228-228.

Median prior therapies: 3 (range 0-8)

Median PFS: 21.8 months (8.5-32 months)

Phase III CABINET trial in GEP NET